Armando López-Guillermo
Hospital Clinic of Barcelona
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Armando López-Guillermo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07254754 · Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · recruiting · DIFFUSE LARGE B-CELL LYMPHOMA · principal investigator
- Ph2NCT01133158 · R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical TrialGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · completed · Non-Hodgkin's Lymphoma
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:54 UTC. The ranking covers the 200 most relevant of 47 PubMed records, and a shared surname and initials can bring in a namesake. All 47 on PubMed
- 1,673 citationsRCR 38.6
- 855 citationsRCR 20.8
- 660 citationsRCR 16.6
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.N Engl J Med · 2018309 citationsRCR 10.4
- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.J Clin Oncol · 2019241 citationsRCR 9.2
- 183 citationsRCR 5.1
- Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.Lancet Haematol · 2019183 citationsRCR 6.1
- 171 citationsRCR 5.2
- 164 citationsRCR 4.0
- 164 citationsRCR 5.0